Search clinical trials for: Nivolumab

Total 1721 results

Icahn School of Medicine at Mount Sinai

Recruiting

Rapid Sequencing of Approved Therapies in Patients With Metastatic or Unresectable Clear Cell Renal Cell Carcinoma

Renal Cell Carcinoma

United States
University of Melbourne
The Alfred

Recruiting

Low Dose Nivolumab in Adults Living With HIV on Antiretroviral Therapy (NIVO-LD)

HIV I Infection

Singapore, Australia
Washington University School of Medicine
The Foundation for Barnes-Jewish Hospital; Curis, Inc.

Recruiting

CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer

Stomach Cancer | Gastric Cancer | Esophageal Cancer | Gastroesophageal Junction Cancer | Esophagus Cancer

United States
BioAtla, Inc.

Recruiting

A Phase 1/2 Study of BA3071 as Monotherapy and in Combination With a PD-1 Blocking Antibody in Patients With Advanced Solid Tumors

Melanoma | Carcinoma | Renal Cell Carcinoma | Small Cell Lung Cancer | Hepatocellular Carcinoma | Gastric Cancer | NSCLC | Cervical Carcinoma | Urothelial Carcinoma | Solid Tumor, Adult

United States, Australia
Exelixis

Recruiting

Study of XL092 in Combination With Immuno-Oncology Agents in Subjects With Solid Tumors (STELLAR-002)

Renal Cell Carcinoma | Hepatocellular Carcinoma | Colorectal Cancer | Solid Tumor | Non-small Cell Lung Cancer | Head and Neck Squamous Cell Carcinoma | Urothelial Carcinoma | Metastatic Castration-resistant Prostate Cancer

United States, Poland, Spain, Switzerland, Austria, Australia, Belgium, Israel, Italy, New Zealand, France, Germany, United Kingdom
National University Hospital, Singapore
Natera, Inc.; The N.1 Institute for Health (N.1)

Recruiting

Nivolumab and Pembrolizumab Dose Optimisation in Solid Tumours With CURATE.AI Platform and Sequential ctDNA Measurements

Solid Tumor

Singapore
University of Michigan Rogel Cancer Center

Recruiting

Hepatic Ablation of Melanoma Metastases to Enhance Immunotherapy Response, a Phase I Clinical Trial (HAMMER I)

Metastatic Melanoma | Liver Metastases | Melanoma, Mucosal | Melanoma, Ocular | Melanoma, Cutaneous

United States
Bristol-Myers Squibb

Recruiting

A Study of Nivolumab Plus Chemotherapy in First Line Treatment of Adult Participants With Advanced or Metastatic Gastric Cancer (INGA)

Gastric Cancer

Germany
BicycleTx Limited

Recruiting

Study BT7480-100 in Patients With Advanced Malignancies Associated With Nectin-4 Expression

Advanced Solid Tumor

United States, United Kingdom
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

CC-486 and Nivolumab for the Treatment of Hodgkin Lymphoma Refractory to PD-1 Therapy or Relapsed

Recurrent Classic Hodgkin Lymphoma | Refractory Classic Hodgkin Lymphoma

United States
Zhejiang University

Recruiting

Clinical Study of VG161 in Combination With Nivolumab in Subjects With Advanced Pancreatic Cancer

Advanced Pancreatic Cancer

China
YULISU
Ono Pharmaceutical Co. Ltd

Recruiting

Neoadjuvant Nivolumab for Upper Tract Urothelial Carcinoma

Upper Urinary Tract Urothelial Carcinoma

Taiwan
Ezra Cohen

Not yet recruiting

Personalized Immunotherapy in Adults With Upper Gastrointestinal Tract Cancers

Cancer of Gastrointestinal Tract

United States
The Netherlands Cancer Institute
Bristol-Myers Squibb

Recruiting

Neoadjuvant Study With Combination Immuno-oncology for Primary Clear Cell Renal Cell Cancer (NESCIO)

Renal Cell Carcinoma

United Kingdom, Netherlands
Scott Antonia

Recruiting

A Randomized Pilot Study of Evolocumab Plus Nivolumab/Ipilimumab in Treatment-Naïve Patients With Metastatic NSCLC (TOP2101)

Lung Cancer Metastatic

United States
Sir Mortimer B. Davis - Jewish General Hospital

Recruiting

Montreal Immune-Related Adverse Events (MIRAE) Study (MIRAE)

Autoimmune Diseases | Cancer | Immune System Disorder | Inflammatory Reaction

Canada
Bristol-Myers Squibb

Recruiting

A Study to Evaluate Nivolumab in Combination With Ipilimumab Versus Pemetrexed With Cisplatin or Carboplatin for Unresectable Pleural Mesothelioma in Chinese Participants (CheckMate 6DW)

Mesothelioma, Malignant

China
National Cancer Institute (NCI)

Recruiting

BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study

Melanoma | Head and Neck Squamous Cell Carcinoma | Oropharyngeal Squamous Cell Carcinoma | Clinical Stage III Cutaneous Melanoma AJCC v8 | Clinical Stage IV Cutaneous Melanoma AJCC v8 | Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Clinical Stage IV HPV-Mediated... and other conditions

United States
National Taiwan University Hospital

Recruiting

Neo-NTP-CRT for Locally Advanced ESCC (Neo-NTP-CRT)

Locally Advanced Esophageal Squamous Cell Carcinoma

Taiwan
Wuxi People's Hospital

Recruiting

RT-01 Monotherapy and in Combination With Nivolumab in Patients With Advanced Solid Tumors

Advanced Solid Tumor

China
Gustave Roussy, Cancer Campus, Grand Paris

Recruiting

A Pilot Study Evaluating a Ketogenic Diet Concomitant to Nivolumab and Ipilimumab in Patients With Metastatic Renal Cell Carcinoma (KETOREIN)

Metastatic Renal Cell Carcinoma

France
University Hospital Tuebingen

Recruiting

Intrathecal Application of PD1 Antibody in Metastatic Solid Tumors With Leptomeningeal Disease (IT-PD1/ NOA 26) (IT-PD1)

Leptomeningeal Disease

Germany
National Cancer Institute (NCI)
NRG Oncology

Recruiting

Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma

Endometrial Clear Cell Adenocarcinoma | Endometrial Dedifferentiated Carcinoma | Endometrial Endometrioid Adenocarcinoma | Endometrial Mixed Cell Adenocarcinoma | Endometrial Undifferentiated Carcinoma | Recurrent Endometrial Carcinoma | Endometrial Adenocarcinoma | Endometrioid Adenocarcinoma | Endometrial...

United States
National Cancer Institute (NCI)

Recruiting

Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery

Mucosal Melanoma | Anal Melanoma | Bladder Melanoma | Cervical Melanoma | Esophageal Melanoma | Gallbladder Melanoma | Mucosal Melanoma of the Head and Neck | Mucosal Melanoma of the Urinary System | Oral Cavity Mucosal Melanoma | Penile Mucosal Melanoma | Rectal Melanoma | Recurrent Mucosal Melanoma | Sinonasal... and other conditions

United States, Canada
Amgen

Recruiting

Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer (FORTITUDE-102)

Gastric Cancer | Gastroesophageal Junction Adenocarcinoma

Korea, Republic of, United States, Israel, Italy, Spain, Switzerland, Canada, Australia, Germany, United Kingdom, Austria, France, Japan, Taiwan, China, Belgium, Poland, Thailand, Czechia, Singapore, Hungary, Argentina, Brazil, Romania, Portuga... and more
Fred Hutchinson Cancer Center
Amazon.com Services LLC

Recruiting

Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma or Hormone Receptor Positive Her2 Negative Metastatic Refractory Breast Cancer

Anatomic Stage IV Breast Cancer AJCC v8 | Prognostic Stage IV Breast Cancer AJCC v8 | Metastatic Cutaneous Melanoma | Unresectable Cutaneous Melanoma | Clinical Stage III Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 | Pathologic Stage IIID Cutaneous Melanoma AJCC... and other conditions

United States
University of Colorado, Denver
National Comprehensive Cancer Network; Taiho Oncology, Inc.

Recruiting

Oral Decitabine/Cedazuridine (DEC-C) in Combination With Nivolumab for Patients With Mucosal Melanoma

Malignant Melanoma

United States
Sheba Medical Center
Bristol-Myers Squibb

Recruiting

Maintenance Ipilimumab + Nivolumab Post Induction Chemotherapy + SBRT for First Line Treatment Stage IV Pancreatic Cancer

Stage IV Pancreatic Cancer

Israel
Memgen, Inc.
H. Lee Moffitt Cancer Center and Research Institute; Duke Cancer Institute

Recruiting

MEM-288 Oncolytic Virus Alone and in Combination With Nivolumab in Solid Tumors Including Non-Small Cell Lung Cancer

Melanoma | Head and Neck Cancer | Pancreatic Cancer | Solid Tumor | Non Small Cell Lung Cancer | Metastatic Cancer | Triple Negative Breast Cancer | Advanced Cancer | Merkel Cell Carcinoma | Cutaneous Squamous Cell Carcinoma

United States
Gangnam Severance Hospital

Recruiting

Investigator-initiated Pilot Study to Investigate the Efficacy and Safety of Immuncell-LC in Combination With Nivolumab (Opdivo) in Subjects With Advanced or Recurrent Gastric Cancer

Gastro-esophageal Junction Cancer | Relapsed or Advanced Gastric Adenocarcinoma

Korea, Republic of
M.D. Anderson Cancer Center
Bristol-Myers Squibb; Exelixis

Recruiting

A Phase II Study of Nivolumab With Ipilimumab and Cabozantinib in Patients With Untreated Renal Cell Carcinoma Brain Metastases

Renal Cell Carcinoma | Brain Metastases

United States
Akamis Bio
Bristol-Myers Squibb

Recruiting

Study of NG-641 in Combination With Nivolumab in Metastatic or Advanced Epithelial Tumours (NEBULA)

Metastatic Cancer | Epithelial Tumor

United States, United Kingdom
Emory University
National Cancer Institute (NCI)

Recruiting

Brentuximab Vedotin and Nivolumab for the Treatment of Relapsed/Refractory Classic Hodgkin Lymphoma Previously Treated With Brentuximab Vedotin or Checkpoint Inhibitors

Recurrent Classic Hodgkin Lymphoma | Refractory Classic Hodgkin Lymphoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Phase I/II Randomized Study of NBTXR3 Activated by Abscopal or RadScopal Radiation in Combination With Immunotherapy (Anti-PD-1/L-1) for Patients With Advanced Solid Malignancies

Advanced Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Metastatic Malignant Neoplasm in the Liver | Metastatic Malignant Neoplasm in the Lung

United States
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Recruiting

A Study of Docetaxel for Injection (Albumin-bound) in Combination With Nivolumab in Patients With Head and Neck (SCCHN)

Squamous Cell Carcinoma of Head and Neck

China
Fundación GECP

Recruiting

Nivolumab and Ipilimumab Plus Chemotherapy for Patients With Stage IV Lung Cancer With Brain Metastases (NIVIPI-Brain)

Lung Cancer | Non Small Cell Lung Cancer | Brain Metastases, Adult

Spain
Shanghai Zhongshan Hospital

Not yet recruiting

Gut Microbiota Reconstruction for NSCLC Immunotherapy

Non-Small Cell Lung Cancer

China
HonorHealth Research Institute
NovoCure Ltd.

Recruiting

Single Arm Trial of Tumor-Treating Fields in Combination With Nivolumab and Ipilimumab in Metastatic Uveal Melanoma

Uveal Melanoma

United States
Baylor College of Medicine
National Cancer Institute (NCI); Stand Up To Cancer; Center for Cell and Gene... and other collaborators

Recruiting

HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma

Sarcoma | Soft Tissue Sarcoma | Osteosarcoma | Ewing Sarcoma | Rhabdomyosarcoma | Synovial Sarcoma | HER-2 Protein Overexpression | Undifferentiated Sarcoma

United States
Memorial Sloan Kettering Cancer Center

Recruiting

Adding Certolizumab to Chemotherapy + Nivolumab in People Who Have Lung Cancer That Can Be Treated With Surgery

Lung Cancer | Lung Cancer Stage III | Lung Cancer Stage II

United States
Assistance Publique - Hôpitaux de Paris

Recruiting

Assessing the Tolerance and Clinical Benefit of feCAl tranSplantation in patientS With melanOma (PICASSO)

Melanoma

France
University of Wisconsin, Madison
Bristol-Myers Squibb; National Cancer Institute (NCI); United States Department... and other collaborators

Recruiting

Androgen Deprivation, With or Without pTVG-AR, and With or Without T-Cell Checkpoint Blockade, in Patients With Newly Diagnosed, High-Risk Prostate Cancer

Prostate Cancer

United States
University of Southampton
Bristol-Myers Squibb

Recruiting

Temozolomide + Nivolumab in MGMT Methylated Oesophagogastric Cancer (ELEVATE)

Cancer of Esophagus | Adenocarcinoma - GEJ

United Kingdom
St. Petersburg State Pavlov Medical University

Recruiting

A Study of Safety and Efficacy of PET-adapted Treatment With Nivolumab at the Fixed Dose 40 mg, Ifosfamide, Carboplatin, Etoposide (NICE-40) in Patients With Relapsed/Refractory Hodgkin Lymphoma (NICE-40)

Hodgkin Lymphoma

Russian Federation
University Health Network, Toronto
Bristol-Myers Squibb

Recruiting

Using ctDNA to Determine Therapies for Lung Cancer (ctDNA Lung RCT)

Non Small Cell Lung Cancer | Circulating Tumor DNA | Complete Surgical Resection

Canada
University Health Network, Toronto
Bristol-Myers Squibb

Recruiting

Study of Nivolumab-Ipilimumab and cfDNA in Lung Cancer (ATLAS)

Non Small Cell Lung Cancer

Canada
M.D. Anderson Cancer Center

Recruiting

Nivolumab for the Treatment of Metastatic or Unresectable Solid Tumors With ARID1A Mutation and CXCL13 Expression

Metastatic Malignant Solid Neoplasm | Unresectable Solid Neoplasm

United States
Maastricht University Medical Center
Erasmus Medical Center; Jules Bordet Institute; Academisch Ziekenhuis Maastricht

Recruiting

Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI

Unspecified Adult Solid Tumor, Protocol Specific

Netherlands, Belgium
M.D. Anderson Cancer Center

Recruiting

Nivolumab for the Treatment of Patients With Metastatic Urothelial Cancer With ARID1A Mutation and Stratify Response Based on CXCL13 Expression

Metastatic Bladder Urothelial Carcinoma | Metastatic Renal Pelvis Urothelial Carcinoma | Metastatic Ureter Urothelial Carcinoma | Metastatic Urethral Urothelial Carcinoma | Metastatic Urothelial Carcinoma | Recurrent Bladder Urothelial Carcinoma | Recurrent Renal Pelvis Urothelial Carcinoma | Recurrent... and other conditions

United States
Brown University
Bristol-Myers Squibb

Recruiting

BrUOG 397: NEO Rad (LOW): Neoadjuvant Low Dose Stereotactic Body Radiotherapy, Ipilimumab and Nivolumab

Non Small Cell Lung Cancer

United States

Search clinical trials for: Nivolumab

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ethiopia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations